Drug Profile
S 42909
Alternative Names: S-42909Latest Information Update: 25 Jul 2022
Price :
$50
*
At a glance
- Originator Servier
- Developer ILKOS THERAPEUTICS; Servier; Servier Canada
- Class Antiulcers; Polyphenols; Skin disorder therapies; Small molecules
- Mechanism of Action Matrix metalloproteinase 2 inhibitors; NADPH oxidase inhibitors; Plasminogen activator inhibitor-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Leg ulcer
- No development reported Wounds
Most Recent Events
- 25 Jul 2022 S 42909 is still in a phase II trial for Leg ulcer (In adults, In the elderly) in Argentina, Austria, Brazil, Canada, Czech Republic, Denmark, Germany, Hungary, Italy, Poland, Slovakia, Spain and USA (PO) (NCT03077165) (EudraCT2016-004143-36) (Ilkos Therapeutics pipeline, July 2022)
- 22 Jan 2020 Ilkos Therapeutic completes a phase II trial in Leg ulcer (In adults, In the elderly) in Argentina, Austria, Brazil, Canada, Czech Republic, Denmark, Germany, Hungary, Italy, Poland, Slovakia, Spain and USA (PO) (NCT03077165) (EudraCT2016-004143-36)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Leg ulcer(In volunteers) in France (PO, Tablet)